Avalyn Pharma Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 58/100
What the filing says
Avalyn Pharma completed enrollment of its MIST Phase 2b trial with 398 patients (vs. 375 target) for AP01 inhaled pirfenidone in progressive pulmonary fibrosis; topline data expected H2 2027. The company ended Q2 2026 with $413.5M in cash and marketable securities (including $316.6M from May 2026 IPO), providing runway into 2029. Q2 2026 R&D expenses were $24.7M vs. $17.9M in Q2 2025; net loss was $28.9M vs. $20.2M in Q2 2025.
Why this rating
Trial completion is operationally positive but results unknown until H2 2027. IPO proceeds provide 3-year runway, reducing financing risk. Burn rate ~$15M/quarter; cash position is 3x total assets. Moderate significance: good execution on pipeline, but company remains pre-revenue and outcome-dependent.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.